What is HC Wainwright's Estimate for ESPR FY2028 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at HC Wainwright lowered their FY2028 earnings per share estimates for Esperion Therapeutics in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of $0.16 for the year, down from their previous estimate of $6.05. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.28) per share.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $51.63 million during the quarter, compared to the consensus estimate of $55.44 million. During the same period last year, the firm earned ($0.37) earnings per share.

ESPR has been the subject of several other research reports. Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price objective for the company. StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. JMP Securities reaffirmed a "market outperform" rating and issued a $7.00 price objective on shares of Esperion Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $7.25.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock traded down $0.11 during mid-day trading on Monday, hitting $2.00. 3,472,693 shares of the company were exchanged, compared to its average volume of 5,135,154. The business's 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $2.17. The company has a market capitalization of $393.09 million, a P/E ratio of -3.12 and a beta of 1.03. Esperion Therapeutics has a 12-month low of $1.58 and a 12-month high of $3.94.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in shares of Esperion Therapeutics during the third quarter worth about $606,000. Anson Funds Management LP acquired a new position in shares of Esperion Therapeutics during the third quarter worth about $540,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock worth $1,174,000 after purchasing an additional 295,378 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Esperion Therapeutics by 66.8% during the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company's stock worth $995,000 after purchasing an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP lifted its stake in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after purchasing an additional 6,483,070 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.